
What is claimed is:

1. Use of an effective amount of a glutamate modulator in the manufacture of a medicament in treating cancer in a patient in need thereof, wherein said medicament is to be administered in combination with an immunotherapeutic anti-cancer agent; and wherein the glutamate modulator has the following formula:



,

wherein the immunotherapeutic anti-cancer agent is a checkpoint inhibitor, wherein the checkpoint inhibitor is an inhibitor of a checkpoint receptor selected from PD-1~~,~~ and PD-L1, wherein the inhibitor of PD-1 is an anti-PD-1 antibody selected from nivolumab, pembrolizumab and pidilizumab, and wherein the inhibitor of PD-L1 is anti-PD-L1 antibody selected from BMS-936559, durvalumab, atezolizumab, and avelumab.

2. The use of claim 1 wherein the inhibitor of PD-1 is ~~an anti-PD-1 antibody selected from~~ nivolumab~~, pembrolizumab and pidilzumab~~.

3. The use of claim 1 wherein the inhibitor of PD-~~L~~1 is pembrolizumab~~anti-PD-L1 antibody selected from BMS-936559, durvalumab, atezolizumab, and avelumab~~.

4. The use of claim 1 wherein the inhibitor of PD-~~L~~1 is pidilizumab~~a peptide~~.

5. The use of claim 1 wherein the glutamate modulator and the immunotherapeutic anti-cancer agent are capable of providing a Mouse Survival Ratio of at least 2.0 at day 60 (MSR_{60}).